Loading company…
Veloxis Pharmaceuticals develops immunosuppressive therapies for transplant patients, including the investigational drug pegrizeprument.
Founded in 2007 and based in Copenhagen, Denmark, Veloxis Pharmaceuticals A/S develops therapies for transplant healthcare. Its lead candidate, pegrizeprument (VEL-101), is a subcutaneous CD28 co-stimulation blocker for maintenance immunosuppression in kidney transplantation. The company was co-founded by Mohammad Sohail and was acquired in a trade sale by Asahi Kasei Corporation for DKK 8,900.00 mn. It has completed 8 deals. It reported zero revenue in 2022 and EBITDA of DKK -214,000 in 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in